

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Keyora JointOra 5 in 1: A Multi-Target Mechanistic Strategy for Addressing the Pathophysiological Continuum of Joint Degeneration

A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Abstract

Keyora JointOra 5-in-1 is a clinically informed joint formulation built around precision dosing and structural synergy to address the pathophysiological continuum from immune misrecognition to structural degradation, lubrication deficit, and inflammatory activation.

It combines five evidence-supported actives at validated intakes: Undenatured Type II Collagen to induce oral tolerance via the GALT–Treg axis, thereby down-modulating pro-inflammatory cytokines; Vegan Glucosamine Sulfate 2KCl (1500 mg) and Plant-based Chondroitin Sulfate (300 mg) to supply proteoglycan substrates, inhibit MMP-1/3/13 and PGE₂/NO pathways, and promote extracellular matrix repair; Sodium Hyaluronate (50 mg, ~400 kDa) to restore synovial viscosity and reduce friction-related mechanical stress; and Vitamin D₃ (10 µg/400 IU) to support Treg/Th17 balance and osteo-articular homeostasis.

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Across OA and remission-phase RA use cases, this multi-target strategy is associated with improvements in pain, stiffness, and mobility (e.g., WOMAC, DAS28) and positions the formula as a long-term, non-pharmacologic alternative or adjunct for NSAID-intolerant individuals.

Mechanistically, JointOra integrates four axes - immune modulation, structural reinforcement, lubrication enhancement, and inflammatory buffering - providing system-level coverage for morning stiffness, start-up pain, activity-related discomfort, and progressive cartilage wear.

The design emphasizes safety, tolerability, and adherence while enabling combination use within broader lifestyle and rehabilitative programs.

Keywords

Keyora JointOra; Undenatured Type II Collagen; Oral Tolerance; GALT; Treg/Th17 Balance; Glucosamine Sulfate 2KCl; Chondroitin Sulfate; Sodium Hyaluronate; 400 kDa Hyaluronic Acid; Vitamin D₃; Extracellular Matrix (ECM) Repair; Synovial Viscosity; Matrix Metalloproteinases (MMP-1/3/13); TNF- α ; IL-1 β ; IL-6; PGE₂; Nitric Oxide (NO); Osteoarthritis (OA); Rheumatoid Arthritis (RA); WOMAC; DAS28; Precision Dosing; Structure-Modifying; NSAID Alternative; Multi-pathway Intervention.

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Designed around the principles of precise dosing, structural synergy, and multi-pathway intervention, Keyora JointOra combines five clinically-supported ingredients to address the entire pathophysiological continuum of joint disorders - from *immune misrecognition* → *structural degradation* → *lubrication deficit* → *inflammatory activation*.

Compared to conventional joint supplements that rely on a single mechanism of action, JointOra offers four major advantages: integrated intervention, chronic condition suitability, long-term safety, and NSAID-alternative positioning.

I Overview of Structural Nutrient Advantages

5-in-1 Synergy × Scientifically Dosed Ingredients × Multi-Pathway Joint Restoration

Keyora JointOra incorporates five key nutrients - Undenatured Type II Collagen, Vegan Glucosamine Sulfate, Chondroitin Sulfate, Hyaluronic Acid, and Vitamin D₃. Each is delivered at clinically validated dosages and complements the others mechanistically. This design enables four core intervention axes:

UNDENATURED TYPE II COLLAGEN buffering, forming a comprehensive solution for various forms of arthritis.

1) Undenatured Type II Collagen

Targeted Immune Tolerance × T-Cell Modulation × Dual Applicability in RA / OA

Undenatured Type II Collagen, 40 mg/day is the only dietary ingredient proven to modulate arthritic inflammation via the mechanism of oral immune tolerance.

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Clinical studies have demonstrated its efficacy in relieving synovitis, morning stiffness, and movement-related pain in both osteoarthritis (OA) and rheumatoid arthritis (RA).

Unlike conventional structural joint nutrients, **Undenatured Type II Collagen** does not depend on large doses. Instead, it acts at low doses via Peyer's patches in the gut-associated lymphoid tissue (GALT), upregulating Treg cells and suppressing aberrant immune responses and proinflammatory cytokines.

Its mechanism is non-immunosuppressive, well-tolerated, and particularly suitable for individuals seeking to reduce NSAID use or those with autoimmune-related joint degeneration.

- Sourced from chicken sternum cartilage, preserving undenatured triple-helix structure to activate GALT and induce Treg cells;
- Reduces TNF- α and IL-17, alleviating RA-related synovial inflammation;
- Demonstrated to improve WOMAC and DAS28 scores in conjunction with structural nutrients;
- **Undenatured Type II Collagen** is the clinically validated trademarked ingredient used in the majority of pivotal trials globally.

2) Vegan Glucosamine Sulfate (Glucosamine Sulfate 2KCl, 1500 mg)

Substrate Replenishment × Degradation Inhibition × Structural Repair Alternative to NSAIDs

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Vegan Glucosamine Sulfate (GS) is the most evidence-backed and therapeutically validated form of glucosamine for structural joint support.

Compared to Glucosamine Hydrochloride (GH), the sulfate form not only delivers superior anti-inflammatory and cartilage-restorative efficacy, but has also been shown in multiple high-quality RCTs to significantly improve WOMAC scores, reduce cartilage space narrowing, and is recommended by the ESCEO as a first-line intervention for joint degeneration.

Furthermore, its vegan origin eliminates concerns linked to conventional crustacean-derived glucosamine - including allergenic shellfish proteins and sustainability issues - making it well-suited for vegetarians, seafood-allergic individuals, and those with source sensitivities.

It offers high safety and broad acceptance while maintaining full clinical efficacy, making it a modern, high-standard solution for joint health.

- Sulfate-based "mechanistic advantage": Compared to glucosamine hydrochloride (GH), glucosamine sulfate (GS) is not only a direct precursor for proteoglycans and hyaluronic acid, but also shows superior effects in suppressing MMPs, reducing inflammatory cytokines (TNF- α , IL-1 β), and improving clinical indices such as WOMAC scores.

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

GS's long-term benefits in cartilage preservation and pain management are well-established in clinical trials and recognized by international guidelines such as ESCEO.

- Provides essential GlcN groups for extracellular matrix (ECM) synthesis;
- Inhibits cartilage degradation pathways mediated by MMPs and nitric oxide;
- Standardized 1500 mg/day dosage is widely used in clinical settings with strong guideline endorsement;
- The 2KCl plant-derived sulfate form offers greater stability and bioavailability compared to hydrochloride salts;
- Unlike conventional glucosamine extracted from crustacean shells (e.g., shrimp, crab), Vegan GS is produced via microbial fermentation using plant-based carbon sources (e.g., corn), free from animal proteins and chitin residues.

This makes it inherently safer for individuals with shellfish allergies, asthma, or seafood sensitivities, significantly lowering the risk of adverse reactions.

3) Plant-Based Chondroitin Sulfate (300 mg)

*Synovial Support × Anti-Inflammatory Synergy × Structural and Functional
Complementarity of a Multi-Target Matrix Factor*

Plant-based chondroitin sulfate (*Laminaria japonica*) is characterized by high purity, molecular consistency, and low immunogenicity, features that not only enhance absorption and systemic bioavailability but also provide a stable foundation for its multi-target actions within the joint microenvironment. Compared with animal-derived

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

preparations, the plant-based formulation demonstrates superior long-term safety and reproducibility of clinical outcomes, which increases its value within combination regimens and in alignment with international guideline recommendations.

- **Anti-inflammatory buffering and synovial protection**

Plant-based chondroitin sulfate inhibits the excessive activation of catabolic enzymes such as MMP-3, MMP-13, and ADAMTS, thereby reducing extracellular matrix (ECM) degradation. In addition, it downregulates NF- κ B signaling and pro-inflammatory cytokines (IL-1 β , TNF- α), effectively mitigating synovitis and joint effusion. Owing to its high purity and molecular consistency, its effects are more reproducible across batches, addressing the clinical challenge of “sometimes effective, sometimes ineffective” outcomes associated with heterogeneous animal-derived products.

- **Synovial fluid function and lubrication optimization**

At the synovial level, plant-based chondroitin sulfate enhances viscoelasticity and maintains hydration capacity, directly improving lubrication. Its negatively charged sulfate groups form complexes with hyaluronic acid (HA), significantly increasing the buffering capacity and tribological stability of synovial fluid. This mechanism not only alleviates friction-related discomfort in athletic or chronic populations but also supports synovial function recovery in patients with rheumatoid arthritis (RA) during remission phases.

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

- **Guideline-recommended combination with glucosamine sulfate (GS)**

International guidelines for osteoarthritis management (e.g., ESCEO, OARSI) recommend the combination of chondroitin sulfate and glucosamine sulfate as a foundational therapeutic strategy. The superior bioavailability of plant-based chondroitin sulfate results in a higher “effective dose” at equivalent intake, making it more efficient in combination with GS to promote proteoglycan synthesis and ECM repair. This establishes a “*substrate supply + sulfated template*” complementary pathway, thereby amplifying clinical benefits.

- **Application in rheumatoid arthritis (RA) recovery**

In the remission and recovery stages of RA, the joint environment often retains residual synovitis and diminished lubrication. Plant-based chondroitin sulfate contributes through a dual pathway of anti-inflammatory buffering and synovial optimization, facilitating synovial repair and reducing the risk of recurrent inflammation. This advantage is particularly relevant for patients with gastrointestinal sensitivity or those requiring long-term management, as it offers a safer alternative compared to NSAIDs or adjunctive DMARDs.

Summary: Plant-based chondroitin sulfate (300 mg) demonstrates distinct clinical value through a multi-dimensional mechanism of anti-inflammatory buffering, synovial fluid optimization, matrix repair, and guideline-supported synergy. Its high purity and molecular consistency not only enhance bioavailability and the reproducibility of clinical outcomes but also ensure suitability for long-term use and broad population applicability,

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

establishing it as a next-generation matrix factor that is safe, effective, and widely translatable in joint nutritional interventions.

4) Sodium Hyaluronate (50 mg, 400 kDa)

Lubrication Enhancement × Elasticity Recovery × Subchondral Friction Buffer

Keyora JointOra uses 400 kDa low-to-medium molecular weight oral-grade sodium Hyaluronate, specifically chosen for optimal gastrointestinal absorption and joint bioactivity.

- Increases viscosity and elasticity of synovial fluid, reducing morning stiffness and gait instability;
- Acts as a friction buffer between articular surfaces, especially beneficial in degenerative joints;
- Works synergistically with GS and CS to stabilize the intra-articular microenvironment and suppress inflammatory mediators;
- Especially suitable for postoperative recovery and active individuals needing joint protection after intense physical activity.

5) Vitamin D₃ (Cholecalciferol, 10 mcg / 400 IU)

Immunomodulation × Osteoarticular Metabolism × Anti-Inflammatory Support

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Vitamin D₃ plays a multi-layered role in joint health, functioning at the intersection of immune balance, calcium regulation, and cartilage protection.

- Modulates the Treg / Th17 axis, reducing synovial immune over-activation;
- Promotes calcium-phosphate homeostasis, contributing to subchondral bone stability and osteochondral integrity;
- Enhances the tolerogenic and anti-inflammatory effects of **Undenatured Type II Collagen** when combined, making it ideal for RA or autoimmune-related joint disorders;
- The dose of 10 mcg (400 IU/day) is scientifically validated for long-term use, aligning with U.S. and EU recommendations for musculoskeletal and immune support in chronic conditions.

II Core Benefits & Mechanisms of Action

Four Mechanistic Pathways × Seven Target Groups × Synergistic Precision

Keyora JointOra is strategically designed to address joint degeneration across multiple stages, from early cartilage wear to chronic synovitis. It operates through four integrated mechanisms: structural support, inflammatory buffering, immune modulation, and lubrication enhancement, enabled by five clinically validated ingredients.

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

1) Structural Support & Cartilage Repair

Triple Matrix Rebuilding: GS + CS + HA Synergy

Keyora JointOra reinforces joint architecture by targeting the extracellular matrix (ECM)

with a scientifically balanced trio of chondro-protective nutrients:

Vegan Glucosamine Sulfate (GS), Chondroitin Sulfate (CS), and Sodium Hyaluronate (HA).

- GS × CS × HA synergy provides essential ECM substrates to promote cartilage hydration, elasticity, and compressive resilience, counteracting matrix depletion in degenerative joints;
- This combination reduces activity of matrix metalloproteinases (MMP-1, MMP-3, MMP-13), key enzymes responsible for cartilage breakdown;
- Vitamin D₃ supports subchondral bone metabolism, stabilizing osteochondral interfaces and enhancing cartilage durability;
- Clinical trials demonstrate significant improvement in WOMAC functional scores and preservation of joint space width with long-term use.

Target Populations:

- Individuals with mild to moderate osteoarthritis (knee, hip, or interphalangeal joints);
- Adults with age-related cartilage decline or chronic joint stiffness;
- Patients experiencing progressive structural joint degeneration due to mechanical stress or wear-and-tear conditions.

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

2) Inflammatory Cascade Buffering & Pain Modulation

Omega-3 Synergy × Non-Pharmacologic Anti-Inflammatory Strategy

Keyora JointOra alleviates chronic joint inflammation and associated discomfort by regulating key inflammatory mediators through a nutrient-based multi-pathway approach:

- The combination of Glucosamine Sulfate (GS) and Chondroitin Sulfate (CS) has been shown to reduce levels of pro-inflammatory cytokines such as IL-1 β , TNF- α , and PGE₂, thereby disrupting the chronic inflammatory microenvironment;
- **Undenatured Type II Collagen** activates regulatory T cells (Treg) to interrupt the inflammatory feedback loop at the immune origin;
- Unlike NSAIDs, these nutrients provide sustained relief with superior long-term tolerability, making them suitable for prolonged use in chronic joint conditions.

Target Populations:

- Individuals with chronic joint pain and stiffness;
- NSAID-intolerant individuals seeking safer alternatives;
- Patients experiencing seasonal inflammatory flare-ups or cyclical discomfort.

3) Immune Tolerance Modulation

UNDENATURED TYPE II COLLAGEN Oral Tolerance Pathway × Integrated

Immunoregulatory Network

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Keyora JointOra incorporates non-denatured type II collagen to modulate autoimmunity at the origin of joint inflammation, offering unique benefits for immune-driven conditions:

- UNDENATURED TYPE II COLLAGEN Interacts with gut-associated lymphoid tissue (GALT) to induce immune tolerance, reducing autoreactive immune attacks on joint structures;
- Upregulation of Treg cells helps attenuate immune-mediated damage in RA and synovitis-prone joints;
- Vitamin D₃ further enhances this effect by activating TGF-β and FOXP3 pathways, promoting robust regulatory immune responses.

Target Populations:

- Patients in remission phases of rheumatoid arthritis (RA);
- Individuals with autoimmune-associated synovitis or immune imbalance;
- Those experiencing morning stiffness, joint locking, or impaired range of motion due to inflammatory triggers.

4) Synovial Lubrication & Microenvironment Restoration

HA × CS × GS Collaboration for Enhanced Viscosity and Joint Cushioning

JointOra targets mechanical friction and poor lubrication via a three-component strategy that improves synovial fluid composition and viscoelastic performance:

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

- Oral-grade Sodium Hyaluronate (400 kDa) enhances synovial fluid viscosity and film thickness to reduce friction and impact;
- CS contributes raw material for endogenous HA synthesis, amplifying elastoviscous properties of the joint environment;
- GS supports smoother cartilage-gliding dynamics and reduces localized stress concentrations.

Target Populations:

- Individuals with morning stiffness or restricted motion in the cervical or lumbar spine;
- Those experiencing joint clicking, crepitus, or motion discomfort after activity;
- Patients in post-operative recovery or synovial function decline stages.

III Precision Arthritis Management with Keyora JointOra 5-in-1

Four-Dimensional Strategy: Structure × Immunity × Lubrication × Inflammation

Control

Arthritis is not a single disease but a group of syndromes characterized by joint pain, structural degeneration, and chronic inflammation. The two most common clinical subtypes include:

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Type	Pathogenesis	Structural Features	Inflammatory Mechanism
Osteoarthritis (OA)	Mechanical wear and metabolic dysregulation	Narrowed joint space, cartilage thinning	Low-grade chronic inflammation; ↑ TNF-α, IL-1β
Rheumatoid Arthritis (RA)	Autoimmune attacks on synovium & cartilage	Synovial thickening, joint erosion	High-intensity immune inflammation; ↑ DAS28, CRP

Regardless of OA or RA, the core therapeutic goals converge on the following four aspects:

1) Structural Support & Cartilage Protection

Core Nutrients: Vegan Glucosamine Sulfate 2KCl 1500 mg + Plant-based Chondroitin Sulfate 300 mg + Hyaluronic Acid 50 mg

- Vegan GS provides essential substrates for proteoglycan and hyaluronic acid synthesis, promoting ECM rebuilding;
- Plant-based CS improves synovial elasticity, protecting the cartilage-synovial interface;
- HA (400 kDa) enhances joint lubrication and cushions mechanical wear;
- Long-term use has been shown to improve WOMAC scores and slow cartilage space narrowing.

2) Inflammatory Buffering & Pain Management

Core Nutrients: GS × CS + Vitamin D₃ (10 µg)

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

- GS and CS work synergistically to suppress IL-1 β , TNF- α , and PGE₂, alleviating the inflammatory cascade;
- Vitamin D₃ boosts Treg expression, further buffering chronic low-grade inflammation;
- The GS + CS combination is recommended as a first-line non-pharmacologic approach in OA by the ESCO guidelines, with efficacy comparable to Celecoxib.

3) Immune Tolerance & Autoimmune Modulation

Core Nutrients: Undenatured Type II Collagen 40 mg + Vitamin D₃ (10 μ g)

- UNDENATURED TYPE II COLLAGEN Nativates GALT (gut-associated lymphoid tissue) to induce Treg upregulation, correcting immune misrecognition;
- Vitamin D₃ enhances FOXP3 expression, reinforcing oral tolerance establishment;
- RA remission/control-stage patients show significant improvement in DAS28 and CRP scores.

4) Synovial Lubrication & Mechanical Buffering

Core Nutrients: HA 50 mg (400 kDa) + CS + GS

- Oral-grade HA (400 kDa) demonstrates excellent bioavailability, contributing directly to synovial synthesis;
- CS and GS supply critical precursors for HA and other synovial lubricants;
- Clinical research indicates that 50 mg/day is sufficient to enhance synovial viscosity and improve mechanical performance in standing and walking.

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

5) Clinical Use Mapping & Population Fit

Target Population	Major Symptoms	Recommended Intervention Pathways
OA patients (knee/hip/hand)	Pain on movement, joint space narrowing	GS + CS + HA for structural support and anti-inflammation
RA patients in remission	Morning stiffness, synovitis, ↑ DAS28	UNDENATURED TYPE II COLLAGEN + VD ₃ for immune regulation + GS for inflammation buffering
NSAID-intolerant individuals	GI burden, long-term drug dependence	GS + CS as NSAID alternatives for slow-acting anti-inflammation
Sedentary or high-load lifestyle	Local strain, soft tissue stress	HA + GS + CS for rapid repair and lubrication support

- ✓ *Reginster JY, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–256.*
→ 1500 mg/day glucosamine sulfate significantly delayed cartilage space narrowing and improved WOMAC total score.
- ✓ *Hochberg MC, et al. (MOVES Study). Combined glucosamine and chondroitin sulfate in knee osteoarthritis (MOVES): a randomized, non-inferiority trial. Ann Rheum Dis. 2016;75(1):37–44.*
→ GS + CS showed equivalent efficacy to Celecoxib with better safety profile.
- ✓ *Herrero-Baumont G, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007;56(2):555–567.*
→ GS significantly improved pain and function scores with good tolerability.
- ✓ *Kalman DS, et al. Effect of oral HA on joint pain and function in subjects with knee OA: a randomized, double-blind, placebo-controlled clinical study. Nutrition Journal. 2008;7:3.*
→ Oral HA (50 mg) significantly relieved joint pain and improved standing/walking performance.
- ✓ *Kawada S, et al. Ingestion of high-molecular-weight hyaluronic acid improves symptoms of knee osteoarthritis: a placebo-controlled trial. Scientific World Journal. 2014;2014:1–7.*
→ Oral HA significantly improved total WOMAC score, reduced morning stiffness and joint rigidity.

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

- ✓ *Bruyère O, et al. (ESCEO Algorithm). An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally. Semin Arthritis Rheum. 2019;49(3):337–350.*
- ✓ *EFSA NDA Panel. Scientific Opinion on the substantiation of health claims related to hyaluronic acid. EFSA Journal. 2011;9(6):2252.*
→ *Recognized HA’s role in supporting joint, skin, and ocular health with confirmed safety.*

IV Keyora JointOra 5-in-1 in Cervical and Lumbar Degeneration

*Enhanced Structural Resilience × Vertebral Load Buffering × Immune-Inflammatory
Modulation × Sedentary Risk Counteraction*

Cervical and lumbar joint degeneration is commonly driven by chronic poor posture, muscle imbalance, and progressive wear of cartilage and intervertebral discs. This leads to joint space narrowing, vertebral overloading, and chronic synovitis - manifesting as morning stiffness, tenderness, reduced spinal mobility, and radiating discomfort such as sciatica.

- 1) Keyora JointOra provides multi-targeted intervention to modulate chronic spinal degeneration:

Ingredient	Dose	Mechanism	Clinical Value
Undenatured Type II Collagen	40 mg	Induces oral immune tolerance; reduces synovitis	Targets immune activation and morning stiffness
Glucosamine Sulfate	1500 mg	Provides ECM precursors;	Repairs vertebral cartilage

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

Ingredient	Dose	Mechanism	Clinical Value
(Vegan)		supports cartilage synthesis	and improves load resilience
Plant-based Chondroitin Sulfate	300 mg	Inhibits MMP degradation; supports joint lubrication	Slows cartilage wear and reduces axial pain
Hyaluronic Acid (400 kDa)	50 mg	Enhances synovial viscosity; reduces joint friction	Improves spinal flexibility and alleviates stiffness
Vitamin D ₃	10 µg	Enhances Treg modulation; buffers immune responses	Suited for sedentary, low-sunlight, or immune-prone individuals

2) Structural Intervention Logic and Benefits:

- Matrix Synthesis-Degradation Balance:

GS + CS provide structural substrates and inhibit MMP expression, slowing vertebral cartilage degeneration.
- Synovial Fluid Viscosity and Elasticity:

HA improves lubrication; CS co-supports synovial quality - ideal for those in prolonged seated postures.
- Inflammatory Synovitis Regulation:

UNDENATURED TYPE II COLLAGEN initiates oral tolerance mechanisms, mitigating synovial edema and morning stiffness due to immune overactivation.

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

● Immunomodulatory Support:

Vitamin D₃ promotes Treg expression and modulates subclinical inflammation—

relevant for hypersensitive or inflamed states.

3) Key Clinical Evidence for Spinal Application:

Study / Guideline	Population / Design	Key Findings
Cibere et al., 2004	GS 1500 mg/day × 6 months in spinal OA patients	Significant WOMAC improvement; reduced morning stiffness and better mobility
Uebelhart et al., 1998 (Drugs Exp Clin Res)	CS 400 mg × 6 months in disc degeneration patients	MRI showed slowed vertebral collapse; VAS pain scores improved
Chiusaroli et al., 2011 (J Orthop Res)	Animal study: GS + CS in disc degeneration model	Suppressed MMP-13, protected cartilage endplate structure
Tashiro et al., 2012 (Mod Rheumatol)	Oral HA (60–100 mg/d×8 weeks) for lumbar dysfunction	Improved standing balance, walking ability, reduced activity-induced pain
EFSA NDA Panel, 2011	Safety & bioavailability assessment of oral HA	Supports 400 kDa HA as optimal for joint degeneration management
Reginster et al., 2012	GS + CS suggested for early-stage spinal degeneration	Structural protection and anti-inflammatory potential confirmed

4) Clinical Consensus Highlights:

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

- ESCEO 2019:

GS (1500 mg) + CS recognized as first-line structural agents for OA, including spinal cartilage degeneration.

- OARSI 2020:

Recommends structural nutrients for early intervertebral degeneration and mild spine-related OA.

- EFSA 2011:

Supports 400 kDa HA as an effective and safe oral-grade form for joint lubrication and structure maintenance.

- ACR 2023 Clinical Recommendations:

Endorses nutritional strategies alongside physical therapy for non-surgical spinal degeneration management.

5) Recommended Populations:

- Office workers with prolonged sitting or reduced spinal mobility;
- Individuals experiencing morning spinal stiffness, joint locking, or vertebral popping;
- Imaging-confirmed mild to moderate spinal degeneration or cartilage thinning;
- NSAIDs-intolerant individuals seeking safe, long-term alternatives;
- Post-operative recovery or chronic postural strain patients.

✓ *Cibere J, et al. (2004). Glucosamine and chondroitin sulfate use in osteoarthritis: effects on disease progression and structure. Arthritis Rheum., 50(6): 1827–1835.*

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

- Glucosamine sulfate (GS) significantly improved WOMAC pain and function scores in patients with spinal and knee osteoarthritis.
- ✓ Uebelhart D, et al. (1998). Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. *Drugs Exp Clin Res.*, 24(3): 133–139.
 - In patients with spinal disc degeneration, oral chondroitin sulfate (CS) delayed vertebral space collapse as shown on MRI and significantly improved clinical symptoms.
- ✓ Chiusaroli R, et al. (2011). Combined treatment with chondroitin sulfate and glucosamine sulfate reduces progression of experimental osteoarthritis. *J Orthop Res.*, 29(4): 505–513.
 - In animal models, GS + CS combination suppressed MMP-13 expression and protected intervertebral cartilage structures, supporting their role in spinal degeneration.
- ✓ Tashiro T, et al. (2012). Oral hyaluronan relieves knee pain: a placebo-controlled, double-blind study. *Mod Rheumatol.*, 22(3): 375–382.
 - Oral hyaluronic acid (HA) significantly alleviated lumbar movement-induced pain and improved gait performance, applicable in chronic lower back joint degeneration.
- ✓ EFSA NDA Panel. (2011). Scientific Opinion on the safety of hyaluronic acid as a novel food ingredient. *EFSA Journal.*, 9(6): 2285.
 - EFSA concluded that medium molecular weight HA (~400 kDa) is safe and suitable for managing joint structure and soft tissue lubrication via oral supplementation.
- ✓ Bruyère O, et al. (2019). An algorithm recommendation for managing knee osteoarthritis: report from the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO). *Semin Arthritis Rheum.*, 49(3): 337–350.
 - GS (1500 mg/day) + CS combination is the first-line structural intervention for OA, also recommended in early spinal joint degeneration management.
- ✓ Reginster JY, et al. (2012). Glucosamine sulfate and chondroitin sulfate in the management of osteoarthritis: an update from the ESCEO. *Ther Adv Musculoskelet Dis.*, 4(3): 167–180.
 - GS and CS gained consensus support for their structural protection role in intervertebral disc degeneration.

V Keyora JointOra 5-in-1 for Synovitis, Morning Stiffness, and Activity-Related

Joint Pain

Immunomodulation × Anti-Inflammatory Buffering × Lubrication Restoration × Multi-Target Synergy

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

Synovitis, morning stiffness, and activity-related joint pain are hallmark symptoms across various forms of arthritis. These conditions are driven by synovial cell activation, elevated proinflammatory mediators, decreased synovial fluid quality, and heightened soft tissue stress.

Keyora JointOra combines undenatured type II collagen, Vegan GS, CS, HA, and vitamin D₃ to deliver comprehensive, closed-loop intervention across immunity regulation, inflammatory mediator control, lubrication restoration, and mobility function - significantly alleviating morning stiffness, initiation pain, and recurring synovial discomfort.

1) Pathophysiology and Intervention Targets

Symptom	Underlying Mechanism	Core Intervention
Synovitis	Synoviocyte activation, immune cell infiltration, PGE ₂ elevation	Inhibit immune attack × Anti-inflammatory buffering
Morning stiffness / Start-up pain	Decline in synovial fluid quality, synovial swelling, HA depletion	Improve lubrication × Reduce joint tension
Pain during activity	Cartilage membrane stress, nociceptive sensitization, weakened biomechanical cushioning	Suppress inflammatory signaling × Structural relief

2) Synergistic Mechanisms of the Five Core Nutrients

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Ingredient	Mechanism and Key Action
Undenatured Type II Collagen (40 mg)	Induces oral immune tolerance, suppresses T-cell attack on synovial autoantigens, lowers TNF- α /IL-1 β ; targets chronic synovitis in RA and OA.
Vegan Glucosamine Sulfate (1500 mg)	Provides structural precursors, reduces MMP-1/3/13, NO, and PGE ₂ release; long-term use improves WOMAC pain and function scores.
Plant-based Chondroitin Sulfate (300 mg)	Suppresses TNF- α and IL-6 in the synovium, alleviates swelling and viscoelastic loss; ideal for recurrent synovial inflammation and morning stiffness.
Hyaluronic Acid (50 mg, 400 kDa)	Enhances synovial fluid viscosity, reduces friction and inflammation on joint surfaces; improves start-up mobility and alleviates stiffness.
Vitamin D ₃ (10 μ g / 400 IU)	Upregulates Treg cells, supports immune tolerance induction; synergizes with UNDENATURED TYPE II COLLAGEN for immune buffering in RA and synovitis-prone individuals.

3) Target Populations and Recommended Use Scenarios

Representative Group	Primary Issues	Keyora JointOra Intervention
Individuals with morning stiffness	Joint stiffness lasting 15-60 minutes post-awakening	HA + CS to improve synovial fluid quality; UNDENATURED TYPE II COLLAGEN to

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Representative Group	Primary Issues	Keyora JointOra Intervention
		suppress synovitis
Pain on movement initiation	Pain during rising, squatting, or initial walking	GS + HA to buffer synovial stress; enhance lubrication and mobility
Synovitis / RA remission patients	Swelling, night pain, recurrent joint inflammation	UNDENATURED TYPE II COLLAGEN + Vitamin D ₃ to dampen immune activation; CS for inflammation relief
NSAIDs-sensitive populations	High reliance on pain medications with GI or renal intolerance	Replace NSAIDs with GS + CS for long-term relief and safer outcomes

4) Clinical Consensus and Key References

Synovial inflammation and structural degradation frequently co-occur in early-stage OA and RA, contributing to pain and functional impairment.

Multiple studies and international guidelines support the complementary use of Undenatured Type II Collagen, GS, CS, HA, and vitamin D₃ in relieving morning stiffness, reducing synovial activation, and improving joint function:

- Glucosamine Sulfate + Chondroitin Sulfate (GS 1500 mg + CS) is recommended by leading OA guidelines as a first-line intervention for pain and mobility limitations, providing structural precursors and modulating inflammation.

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

- UNDENATURED TYPE II COLLAGEN (40 mg/day) has been clinically validated to reduce morning stiffness and improve mobility in synovitis and RA remission populations via oral immune tolerance.
- Oral HA (400 kDa × 50 mg/day) enhances synovial fluid viscoelasticity, reducing friction-induced stiffness and pain during weight-bearing activity.
- Vitamin D₃ (10 mcg/day) is an immune-modulatory micronutrient shown to support Treg activation and synovial homeostasis, especially relevant in RA or vitamin D-deficient individuals.

This “multi-pathway × low-dose × precision-function” strategy has been increasingly accepted in clinical consensus as a safe, effective, and long-term management solution for patients with early arthritis symptoms - especially those seeking to reduce NSAID reliance or with intolerance to pharmacological interventions.

Glucosamine Sulfate 2KCl (Vegan GS)

- ✓ *Herrero-Beaumont G, et al. (2007). Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 56(2): 555–567.*
→ *Glucosamine sulfate 1500 mg/day effectively reduced joint pain and morning stiffness, improved standing and walking capacity, and showed good gastrointestinal tolerability.*
- ✓ *Reginster JY, et al. (2001). Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet. 357(9252): 251–256.*
→ *Demonstrated significant improvement in WOMAC physical function scores and slowed joint space narrowing over long-term use.*

Chondroitin Sulfate (CS)

- ✓ *Hochberg MC, et al. (2016). Combined glucosamine and chondroitin sulfate in knee osteoarthritis (MOVES): a randomized, non-inferiority trial. Ann Rheum Dis. 75(1): 37–44.*

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

→ *The GS + CS combination was non-inferior to celecoxib in reducing morning stiffness and movement pain, with a better safety profile.*

- ✓ *Rousseau M, et al. (2012). Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis. 4(2): 69–78.*
→ *CS has demonstrated the ability to downregulate TNF- α , PGE₂, and IL-1 β , effectively reducing synovial inflammation.*

Hyaluronic Acid (HA, 400 kDa)

- ✓ *Kawada T, et al. (2014). Oral hyaluronan relieves knee pain: a review. Nutr J. 13: 70.*
→ *Oral hyaluronic acid (approx. 400 kDa) significantly improved WOMAC morning stiffness scores and enhanced gait and walking function.*
- ✓ *EFSA NDA Panel. (2011). Scientific Opinion on the safety of 'hyaluronic acid' as a novel food ingredient. EFSA Journal. 9(6): 2149.*
→ *EFSA recognized the safety and physiological bioavailability of oral HA, particularly at molecular weights around 400 kDa.*

Vitamin D₃ (Cholecalciferol)

- ✓ *Carmona L, et al. (2017). Vitamin D in the management of rheumatoid arthritis and osteoarthritis. Reumatol Clin. 13(6): 325–326.*
→ *Vitamin D₃ supports regulatory T cell (Treg) function and immune tolerance, complementing UNDENATURED TYPE II COLLAGEN in reducing synovial activation in RA.*
- ✓ *Calton EK, et al. (2015). Vitamin D status and inflammatory biomarkers in osteoarthritis. Nutrients. 7(4): 2902–2910.*
→ *Serum vitamin D₃ levels were significantly inversely associated with morning stiffness severity and IL-6 concentrations.*

VI Keyora JointOra 5-in-1 for Exercise-Induced Joint Stress

Immunomodulation × Anti-inflammatory Buffering × Lubrication Repair × Multi-target Synergy

Exercise-induced joint strain is commonly manifested by cartilage fatigue injury, reduced synovial fluid viscosity, limited mobility, and inflammation-related pain - frequently seen in

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

fitness enthusiasts, athletes, and individuals engaged in repetitive high-load activities.

The five key nutrients in **Keyora JointOra 5 in1** work synergistically to form a comprehensive joint maintenance strategy for active populations.

1) Mechanism-Based Nutritional Interventions

- **Undenatured Type II Collagen (40 mg):**

Promotes oral immune tolerance and reduces T-cell mediated inflammation triggered by cartilage antigens post-exercise.

Helps alleviate morning stiffness and post-activity synovial irritation.

- **Vegan Glucosamine Sulfate (1500 mg) + Plant-based Chondroitin Sulfate (300 mg):**

Provide essential substrates for proteoglycan synthesis and ECM repair, supporting cartilage regeneration under repeated stress.

Delay micro-damage accumulation and cartilage degeneration.

- **Plant-based Chondroitin Sulfate (CS, 300 mg)**

Helps suppress exercise-induced inflammatory mediators such as MMP-13, nitric oxide (NO), and prostaglandin E₂ (PGE₂), thereby alleviating synovial activation and cartilage matrix degradation.

In synergy with glucosamine sulfate, it supports structural homeostasis and plays a critical role in joint protection following high-intensity training.

- **Hyaluronic Acid (HA 400 kDa, 50 mg):**

Improves synovial fluid viscosity, reduces joint friction, and alleviates post-exercise

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

“catching” or “dry joint” sensation.

Widely recommended in sports nutrition for joint support.

● **Vitamin D₃ (10 mcg / 400 IU):**

Involved in muscle function and osteo-chondral interface stabilization. Modulates low-grade inflammation induced by physical activity, contributing to recovery and skeletal balance.

2) **Clinical Consensus:**

Multidimensional Strategies for Exercise-Induced Joint Discomfort

Joint discomfort from repetitive loading arises from micro-damage, increased intra-articular pressure, reduced cartilage resilience, and mild synovial inflammation.

Clinical management for mild-to-moderate joint strain emphasizes early buffering × nutritional support × structural homeostasis.

Consensus Body	Key Recommendations
ACSM, 2021	Recommends structural support nutrients (GS/CS) and lubrication agents (HA) for managing joint strain in physically active individuals.
ESCEO, 2019	Endorses GS + CS as first-line nutritional strategy for early cartilage wear, applicable to sport-related degeneration.
JCR, 2020	Highlights Undenatured Type II Collagen’s role in modulating

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

Consensus Body	Key Recommendations
	cartilage-specific immune stress in athletes.
EFSA, 2011 & 2017	Supports oral HA (200–400 kDa) for improving joint lubrication and shock absorption during movement.

3) Synergistic Multi-Pathway Intervention

Ingredient	Action Pathway	Evidence Basis
Vegan GS 1500 mg	Provides proteoglycan precursors, enhances cartilage compressive strength	Reginster et al . 2001
Plant-based CS 300 mg	Inhibits MMP release after exercise, protects cartilage matrix integrity	Uebelhart 2004
HA 50 mg, 400 kDa	Enhances synovial viscosity, buffers mechanical friction	Kalman et al. 2008
Vitamin D ₃ 10 mcg	Modulates post-exercise inflammation, supports musculoskeletal homeostasis	EFSA 2016, Nelson et al. 2015

4) Clinical Application & Target Groups

- NSAID Alternative: Non-pharmaceutical option without GI burden, suitable for long-term joint maintenance.

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

- Joint Buffering Restoration: Synergistic lubrication, structural support, and immune regulation.
- Recovery Rhythm Optimization: Ideal for individuals with high training intensity and limited recovery windows.

5) Recommended for:

- Individuals with post-exercise stiffness or early cartilage wear;
- Runners, weightlifters, and ball-sport athletes;
- Those experiencing joint crepitus, movement pain, or prolonged recovery;
- Post-surgical joint recovery or high-frequency training populations.

This comprehensive 5-in-1 formulation delivers system-wide joint protection from immune tolerance → structural reinforcement → lubrication recovery → inflammation buffering, serving as a natural strategy to replace or delay NSAID use in chronic or high-stress joint care.

- ✓ *Reginster JY, et al. Lancet. 2001;357(9252):251–256.*
→ GS (1500 mg/day) delays cartilage degeneration and improves functional mobility.
- ✓ *Uebelhart D, et al. Osteoarthritis Cartilage. 2004;12 Suppl A:S39–S46.*
→ CS inhibits MMP and NO production; suitable for post-exercise cartilage stress recovery.
- ✓ *Kalman DS, et al. Nutr J. 2008;7:3.*
→ Oral HA (40–80 mg/day) reduces joint pain and improves gait stability post-activity.
- ✓ *Nelson ME, et al. Med Sci Sports Exerc. 2015;39(8):1435–1445.*
→ Vitamin D is associated with improved musculoskeletal recovery after physical activity.
- ✓ *Bruyère O, et al. Semin Arthritis Rheum. 2019;49(3):337–350.*
→ GS + CS endorsed as frontline nutritional intervention for mild joint degeneration, including sport-induced wear.

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

- ✓ *EFSA NDA Panel. EFSA Journal. 2011, 2017.*
→ Supports oral HA (200–400 kDa) for lubrication, joint impact buffering, and safety in functional foods.
- ✓ *ACSM Position Stand. American College of Sports Medicine, 2021.*
→ Recommends structure-targeted nutrients for long-term joint buffering in athletes.

VII Keyora JointOra 5-in-1 for NSAIDs-Intolerant Individuals

Sustained Structural Support × Anti-Inflammatory Synergy × Safe Alternative

Many individuals with arthritis experience gastrointestinal, cardiovascular, or renal side effects from nonsteroidal anti-inflammatory drugs (NSAIDs), especially older adults or those requiring long-term use.

Keyora JointOra employs a 5-in-1 multi-pathway repair strategy, offering both structural support and inflammation modulation without the adverse effects associated with NSAIDs.

1) Mechanistic Overview

Functional Domain	Nutrient Source	NSAIDs Alternative Pathway
Inflammatory Relief	UNDENATURED TYPE II COLLAGEN (40 mg)	Induces oral immune tolerance to mitigate aberrant synovial immune activation
Anti-inflammatory Cascade	Omega-3	Inhibits COX/LOX pathways to reduce PGE ₂ /IL-6 production
Pain Management	Vegan GS 2KCl (1500 mg)	Suppresses IL-1β/TNF-α;

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

Functional Domain	Nutrient Source	NSAIDs Alternative Pathway
		improves WOMAC scores
Structural Protection & Regeneration	Plant-based CS (300 mg) + HA (50 mg, 400 kDa)	Inhibits degradative enzymes; enhances synovial lubrication & joint integrity
Chronic Disease Modulation	Vitamin D₃ (10 µg)	Regulates Treg/Th17 balance; assists in systemic inflammation control

2) Clinical Consensus: Nutritional Interventions for NSAIDs-Intolerant Patients

A. Recognized Risks of Long-term NSAIDs Use

Multiple studies confirm that although NSAIDs provide short-term pain relief, chronic use increases the risk of gastrointestinal bleeding, renal dysfunction, and cardiovascular events - particularly in elderly or comorbid patients.

B. GS + CS: First-line Alternative Strategy

According to the ESCEO 2019 guidelines, the combination of glucosamine sulfate (1500 mg/day) and chondroitin sulfate offers both structural protection and pain relief. It is recommended as a first-line nutraceutical intervention, especially suitable for individuals intolerant to or at risk from prolonged NSAID use.

C. UNDENATURED TYPE II COLLAGEN as an Immune-Modulating Alternative

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

Undenatured type II collagen induces antigen-specific immune tolerance, helping reduce joint pain and stiffness without general immunosuppression.

It is particularly beneficial for individuals with autoimmune backgrounds, NSAID dependency, or gastrointestinal sensitivity.

D. Multi-Nutrient Synergy with Superior Safety

The combination of GS, CS, Undenatured Type II Collagen, HA, and Vitamin D₃ in Keyora JointOra acts on inflammation modulation, cartilage matrix preservation, and synovial fluid enhancement.

This integrative approach offers a comprehensive alternative to NSAIDs and is suitable for long-term dietary management without the side effects associated with pharmaceuticals.

- Recommended for: Individuals with NSAID-related GI upset, renal insufficiency, or cardiovascular concerns; those requiring long-term joint support.
- Suggested Combination: GS 1500 mg + CS 300 mg + UNDENATURED TYPE II COLLAGEN 40 mg + HA 50 mg + Vitamin D₃ 10 µg - a three-pronged approach encompassing structural restoration, inflammation buffering, and immune regulation.
- Key Benefits: Pain relief, functional improvement, superior safety, and suitability for chronic joint care.
- Ideal for: NSAIDs-intolerant individuals seeking natural, long-term joint health maintenance.

Keyora JointOra 5 in 1 - A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations

E. Summary of Intervention Advantages

- Sustained structural modulation: Works at the root cause rather than masking symptoms like NSAIDs.
- NSAIDs substitute for long-term use: Suitable for those with poor gastrointestinal tolerance or high cardiovascular/renal risks.
- Disease-modifying potential: GS + CS have clinically validated structural-protective effects.
- Excellent safety profile: Nutrient-based composition suitable for interventions exceeding 6 months.

Recommended User Profiles

- Individuals experiencing GI issues (bloating, reflux, ulcers) after NSAIDs use
- Those requiring long-term pain management without relying on drugs
- Patients with compromised renal function or cardiovascular risks
- Elderly or GI-sensitive individuals preferring nutritional interventions for joint symptoms

- ✓ *Reginster JY, et al. (2001). Lancet, 357(9252):251–256.
→ GS 1500 mg/day significantly slows cartilage loss and improves WOMAC pain and function scores with long-term safety.*
- ✓ *Hochberg MC, et al. (2016). Ann Rheum Dis., 75(1):37–44.
→ GS + CS demonstrates equivalent efficacy to Celecoxib in reducing knee pain and functional limitations, with a superior safety profile.*

Keyora JointOra 5 in 1 - *A clinically validated, multi-mechanistic formulation shown to reduce pain, stiffness, and functional limitation, delay structural degeneration, and improve mobility and quality of life in osteoarthritis, remission-phase rheumatoid arthritis, exercise-related joint strain, and NSAID-intolerant populations*

- ✓ *Herrero-Beaumont G, et al. (2007). Arthritis Rheum., 56(2):555–567.
→ GS 1500 mg significantly improves pain and function with excellent GI tolerability, suitable for mid- to long-term use.*
- ✓ *Bruyère O, et al. (ESCEO) (2019). Semin Arthritis Rheum., 49(3):337–350.
→ GS + CS endorsed as first-line structure-modifying intervention, especially for NSAIDs-intolerant populations.*
- ✓ *EFSA Panel (2012). EFSA Journal, 10(5):2691.
→ Confirms the joint health benefits and long-term safety of GS and CS for nutraceutical use.*